Short answer. A typical venture debt warrant transfers about 0.5-2% of your company (most deals model near 1%) to the lender, derived from warrant coverage set at 2-10% of the loan amount. Against the 15-25% an equity round would cost, that is cheap dilution. It is still real dilution, so price it before you sign.
Venture debt gets sold as "non-dilutive." It mostly is. But there's a line item lenders rarely lead with: the warrant. That warrant is real equity, and most founders sign it without pricing it. This piece treats the warrant as a decision rather than a footnote, and shows you when the trade is worth it and when it isn't.
Are venture debt warrants actually dilutive?
Yes. Calling venture debt "non-dilutive" is a marketing label that the accounting doesn't support. The principal is debt and dilutes nothing. The warrant attached to it is an equity instrument, and when the lender exercises it, your cap table moves.
The reason founders shrug it off is that the dilution is small. A warrant gives the lender the right to buy stock later at today's price. The dollar value of that stock is set as a slice of the loan, and the loan itself is usually sized at just 20-35% of your last equity round. A small percentage of a fraction buys a thin sliver of your total share count. The number is real, but it stays small. The honest framing is "low-dilution debt," and any lender who calls it truly non-dilutive is selling rather than explaining. For a fuller picture of that trade-off, see our breakdown of venture debt vs equity financing.
What is warrant coverage, and how is it different from dilution?
Warrant coverage is a percentage of the loan amount. Dilution is the percentage of ownership that ends up in the lender's hands. These are two different numbers, and conflating them is the single most common mistake founders make reading their own term sheet. The confusion usually scares people away from a structure that is actually less dilutive than the equity they were about to raise.
The mechanics are plain:
- Warrant value = coverage % × loan amount.
- Strike price is set at your most recent round's price per share, or sometimes at a 15-25% discount to your next round.
- Term runs 5-10 years, so the lender can wait and exercise when your shares are worth the most.
Coverage typically runs 2-10% of the loan, climbing to roughly 15-30% on higher-risk deals. So 10% coverage on a $3M facility means the lender can buy $300,000 of stock at the strike price. That $300,000, against a company worth tens of millions, is what produces the ~1% ownership figure. When a source quotes "0.5-2%," it is describing the dilution outcome. When it quotes "2-10%," it is describing coverage. Read which one your term sheet means before you negotiate it.
How much do the warrants cost in real dollars?
Run the coverage percentage against the loan, then track where the value goes at exit. The cost is small at signing and grows with your valuation.
Here's a worked example: a SaaS company at $4M ARR that closed a Series A and qualifies for a $4M venture debt facility at 10% warrant coverage. That's $400,000 of equity warrants. The strike price is locked at the most recent round's price per share, and the lender can exercise any time over the next 5-10 years. The same deal scales like this as the loan grows:
| Loan amount | Coverage | Warrant value (cost basis) | Approx. equity dilution |
|---|---|---|---|
| $2,000,000 | 10% | $200,000 | ~1% |
| $4,000,000 | 10% | $400,000 | ~1% |
| $5,000,000 | 10% | $500,000 | ~1% |
The dilution percentage holds near 1% across these rows because dilution tracks your company's valuation and share count, not the size of the loan in isolation. Founders also tend to underweight the exit math. If the company's per-share value grows 10x by exit, a $500,000 warrant position can be worth $5M-plus. The lender bought in at the old price and sells at the new one. Your ownership transfer stayed near 1%, but the dollars leaving the table at exit scale with your success. The warrant is cheap when you fail and expensive when you win, which is exactly when you'll feel it.
Is venture debt's all-in cost worth the dilution?
Sometimes it is, and the answer turns on the rest of the price. The warrant is only one part. You have to stack it against the interest and fees, then compare the total to the equity you'd otherwise sell.
In 2026, venture debt interest runs roughly 10-15% all-in, a floating SOFR base around 4.5% plus a spread of about 6-9%. Strong borrowers (tier-1 VC backing, 18-plus months of runway, clean unit economics) land near 9-11%; weaker profiles pay 15-20% and up. On top of interest sit the usual fees: 1-2% upfront, 3-6% at end of term, 0.5-1% a year on the unused line, and a 1-3% prepayment penalty. One detail founders miss on an early acquisition: paying off the loan early kills the interest, but the warrant survives prepayment and still converts at exit. None of those fees touch your cap table, but all of them touch your runway. Lay these costs next to a real cash-flow alternative in our comparison of revenue-based financing vs venture debt for SaaS.
One more reality check: venture debt is gated. You generally need $1M-plus ARR ($2M-plus preferred since the SVB shakeout), a completed Series A, a recent equity round within the last 12-18 months, prior VC backing, and 6-plus months of runway after the loan lands. If you don't already have institutional equity behind you, this door is mostly closed. The full checklist lives in non-dilutive financing requirements. The case for paying the warrant is straightforward. If you need capital and the alternative is an equity round that costs 15-25% of the company, then 10-15% interest plus ~1% warrant dilution is a bargain. The case against it appears when you don't actually need to give up any equity.
When is truly non-dilutive capital the smarter choice?
It wins when your revenue is predictable enough to borrow against it directly. Revenue-based financing (RBF) and CAC-financing carry no warrants and no equity component at all, which means zero dilution rather than low dilution.
The mechanics are different on purpose. RBF qualifies a company with as little as $10K-plus MRR and can close in 24-48 hours, versus the 4-8 weeks venture debt needs. RBF isn't free, it costs an annualized-equivalent of roughly 15-40% depending on how fast you repay, but you keep every share. If you're sizing a facility, how much you can borrow against MRR is the practical starting point.
This is where the EBITCAC framework treats CAC as a capital expenditure rather than an operating expense, and changes the decision. If your customer acquisition spend is booked as an expense, it drags reported profitability and makes growth look like it's burning cash. Treat that same CAC as a capital expenditure, an asset that produces recurring revenue with a measurable payback, and a different question opens up: why dilute equity to fund an asset you can finance against its own cash flows? That's the logic Customer Value Fund is built on. Predictable acquisition economics become the collateral, and no warrant ever touches your cap table. If you want to know which structure fits your numbers, check whether your metrics fit non-dilutive capital before you sign anything with a warrant clause.
Frequently Asked Questions
Is warrant coverage the same as how much equity I lose?
No, and the gap matters. Coverage is a percentage of the loan amount, usually 2-10%, that sets the dollar value of stock the lender can buy. The equity you actually lose is the resulting ownership transfer, typically 0.5-2% of the company, often modeled near 1%. One number describes the size of the warrant; the other describes the dent in your cap table.
What strike price do venture debt warrants use?
The strike is usually fixed at your most recent funding round's price per share, so a Series A warrant strikes at the Series A price. Some deals instead set it at a 15-25% discount to your next round. The lender's right to exercise lasts 5-10 years, so the warrant can sit dormant and then convert near exit, when the spread between strike and market value is widest.
Is venture debt really cheaper than raising equity?
For most growth-stage SaaS, yes, on dilution. An equity round costs roughly 15-25% of the company per raise. Venture debt costs about 10-15% interest plus fees and around 1% warrant dilution. But cheaper than equity is not the same as the cheapest option available. If your revenue qualifies for non-dilutive RBF or CAC-financing, you keep that ~1% too.
Can I avoid warrants entirely?
Yes, by choosing a structure that doesn't use them. Revenue-based financing and CAC-financing carry no warrant and no equity component, so there's nothing to exercise and no dilution at exit. The trade is in cost and structure rather than ownership: you repay from revenue at a 15-40% annualized-equivalent. For companies with predictable acquisition economics, that is often the better deal.
